<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=EBQ%3ATitrated_Oxygen_Therapy_for_COPD_Exacerbation</id>
	<title>EBQ:Titrated Oxygen Therapy for COPD Exacerbation - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=EBQ%3ATitrated_Oxygen_Therapy_for_COPD_Exacerbation"/>
	<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=EBQ:Titrated_Oxygen_Therapy_for_COPD_Exacerbation&amp;action=history"/>
	<updated>2026-04-18T12:26:43Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.38.2</generator>
	<entry>
		<id>https://wikem.org/w/index.php?title=EBQ:Titrated_Oxygen_Therapy_for_COPD_Exacerbation&amp;diff=388353&amp;oldid=prev</id>
		<title>Danbot: Mark as Complete - article has all required sections</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=EBQ:Titrated_Oxygen_Therapy_for_COPD_Exacerbation&amp;diff=388353&amp;oldid=prev"/>
		<updated>2026-03-21T22:11:05Z</updated>

		<summary type="html">&lt;p&gt;Mark as Complete - article has all required sections&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 22:11, 21 March 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l13&quot;&gt;Line 13:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 13:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| fulltexturl=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957540/&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| fulltexturl=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957540/&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| pdfurl=http://www.bmj.com/content/bmj/341/bmj.c5462.full.pdf&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| pdfurl=http://www.bmj.com/content/bmj/341/bmj.c5462.full.pdf&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;| status = Complete&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;}}&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;}}&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Clinical Question==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Clinical Question==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Danbot</name></author>
	</entry>
	<entry>
		<id>https://wikem.org/w/index.php?title=EBQ:Titrated_Oxygen_Therapy_for_COPD_Exacerbation&amp;diff=170054&amp;oldid=prev</id>
		<title>EdMason: Created page with &quot;{{JC info | title= Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial | abbreviation...&quot;</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=EBQ:Titrated_Oxygen_Therapy_for_COPD_Exacerbation&amp;diff=170054&amp;oldid=prev"/>
		<updated>2017-12-10T19:59:01Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;{{JC info | title= Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial | abbreviation...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{JC info&lt;br /&gt;
| title= Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial&lt;br /&gt;
| abbreviation= &lt;br /&gt;
| expansion=&lt;br /&gt;
| published= 2010&lt;br /&gt;
| author= Austin MA et. al.&lt;br /&gt;
| journal= BMJ&lt;br /&gt;
| year= 2010&lt;br /&gt;
| volume=341&lt;br /&gt;
| issue=&lt;br /&gt;
| pages= c5462&lt;br /&gt;
| pmid= 20959284&lt;br /&gt;
| fulltexturl=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957540/&lt;br /&gt;
| pdfurl=http://www.bmj.com/content/bmj/341/bmj.c5462.full.pdf&lt;br /&gt;
}}&lt;br /&gt;
==Clinical Question==&lt;br /&gt;
In the prehospital setting, does titrating oxygen saturation of patients with presumed AECOPD to SpO&amp;lt;sub&amp;gt;2&amp;lt;/sub&amp;gt; 88-92% compared to high flow oxygen for all decrease prehospital and in-hospital mortality?&lt;br /&gt;
&lt;br /&gt;
==Conclusion==&lt;br /&gt;
Compared to high flow oxygen, titrating supplemental oxygen to a target SpO&amp;lt;sub&amp;gt;2&amp;lt;/sub&amp;gt; of 88-92% decreased mortality overall, and decreased hypercapnia and acidosis in patients treated according to protocol.&lt;br /&gt;
&lt;br /&gt;
==Major Points== &lt;br /&gt;
*Patients presenting with dyspnea often receive supplemental oxygen empirically to correct hypoxemia and for symptomatic relief &amp;lt;ref name='ref1'&amp;gt;http://www.clinmed.rcpjournal.org/content/2/5/449&amp;lt;/ref&amp;gt;. However, in patients with COPD hyperoxia has been shown to increase the risk of hypercapnia and acidosis, possibly through decreasing respiratory drive and worsening VQ-mismatch by disruption of hypoxic pulmonary vasoconstriction&amp;lt;ref&amp;gt; https://www.ncbi.nlm.nih.gov/pubmed/3565937&amp;lt;/ref&amp;gt;. Furthermore, observational studies have shown an association between high flow oxygen administration and length of stay, ICU admission and mortality&amp;lt;ref&amp;gt;http://thorax.bmj.com/content/55/7/550&amp;lt;/ref&amp;gt;&amp;lt;ref name='ref1'/&amp;gt;.&lt;br /&gt;
*In this study, paramedics were randomized to administer either high flow oxygen or oxygen titrated to 88-92% SpO&amp;lt;sub&amp;gt;2&amp;lt;/sub&amp;gt; to patients with suspected AECOPD along with standard treatments such as nebulized bronchodilators.&lt;br /&gt;
==Study Design==&lt;br /&gt;
*Cluster randomized controlled single centre parallel group trial.&lt;br /&gt;
*N=405&lt;br /&gt;
**214 had confirmed COPD by PFTs in the past 5 years&lt;br /&gt;
*Enrolment: June 2006 to July 2007&lt;br /&gt;
*Setting: Ambulance service in Hobart, Tasmania, Australia&lt;br /&gt;
==Population==&lt;br /&gt;
===Patient Demographics===&lt;br /&gt;
*All patients (n=405)&lt;br /&gt;
**Male: 49%&lt;br /&gt;
**Mean Age: 69&lt;br /&gt;
*Confirmed diagnosis of COPD (n=214)&lt;br /&gt;
**Male: 48%&lt;br /&gt;
**Mean Age: 68&lt;br /&gt;
**FEV&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt; from most recent PFT: 42.6% predicted&lt;br /&gt;
**Avg Pack years: 45.5&lt;br /&gt;
===Inclusion Criteria===&lt;br /&gt;
*Age ≥ 35&lt;br /&gt;
*Paramedic diagnosis of AECOPD based upon one or more of:&lt;br /&gt;
**appropriateness of symptoms&lt;br /&gt;
**patient-reported history of COPD&lt;br /&gt;
**&amp;gt;10 pack-year smoking history&lt;br /&gt;
&lt;br /&gt;
===Exclusion Criteria===&lt;br /&gt;
&lt;br /&gt;
==Interventions== &lt;br /&gt;
*Paramedics were randomized to administer one of two treatments:&lt;br /&gt;
**Active arm: Oxygen via nasal prongs to target an SpO2 or 88-92% + bronchodilators administered via nebulizer face mask over NPs driven by compressed air.&lt;br /&gt;
**Control arm: High flow oxygen via non-rebreather at 8-10 L/min  + bronchodilators administered via nebulizer with oxygen 6-8L/min&lt;br /&gt;
==Outcomes==&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
===Primary Outcome===&lt;br /&gt;
Prehospital and in-hospital mortality&lt;br /&gt;
*21/226 (9%) in high flow arm vs. 7/179 (4%) in the titrated oxygen arm. RR 0.42 (95% CI: 0.20 to 0.89) p=0.02&lt;br /&gt;
&lt;br /&gt;
===Secondary Outcomes=== &lt;br /&gt;
Incidence of both invasive and non-invasive ventilation&lt;br /&gt;
*19/213 (9%) in high flow arm vs. 13/166 (8%) in the titrated oxygen arm. RR 0.88 (95% CI: 0.45 to 1.72) p=0.7.&lt;br /&gt;
**NIV 9/226 vs 8/179&lt;br /&gt;
&lt;br /&gt;
===Subgroup analysis===&lt;br /&gt;
Confirmed COPD. (Analysis of PFT within last 5 years + medical records by respirologist blinded to treatment allocation)&lt;br /&gt;
*Mortality&lt;br /&gt;
**11/117 (9%) in high flow arm vs. 2/97 (2%) in the titrated oxygen arm. RR 0.22 (95%CI: 0.05 to 0.91) p=0.04&lt;br /&gt;
*Mean blood gasses (note the low # of patients who had blood gasses taken)&lt;br /&gt;
**pH: 7.29 (n=19)  in high flow arm vs. 7.35  (n=19) in the titrated oxygen arm. Mean difference 0.06. p=0.11&lt;br /&gt;
**paCO2 (mmHg) : 77.8  (n=20)  in high flow arm vs. 54.7 (n=20).  Mean difference −23.1. p=0.06.&lt;br /&gt;
&lt;br /&gt;
==Criticisms &amp;amp; Further Discussion==&lt;br /&gt;
*Treatment protocol violation occurred in 56% of patients in the titrated oxygen arm based on ambulance records. All violations involved administration of high flow oxygen at some point pre-hospital.&lt;br /&gt;
*Very few patients had a blood gas taken within 30 minutes of arrival at hospital. Those who did may represent a subgroup of sicker patients.&lt;br /&gt;
*Though hospital staff were instructed to treat according to patient assignment, data regarding whether patients received high flow oxygen in-hospital is largely missing.&lt;br /&gt;
*COPD subgroup defined retrospectively. In addition, this group excluded any patients who lacked recent PFTs, likely excluding patients with ''bona fide'' AECOPD.&lt;br /&gt;
*All patients were admitted to hospital which may not represent the typical disposition of all patients brought to EDs by ambulance for suspected AECOPD.&lt;br /&gt;
*Relatively little use of non-invasive ventilation, though this has been shown to improve hypercapnia and other outcomes in AECOPD.&lt;br /&gt;
*Nebulized treatments administered differently in each group.&lt;br /&gt;
*Single centre study, no blinding post-treatment initiation.&lt;br /&gt;
==External Links==&lt;br /&gt;
&lt;br /&gt;
==See Also==&lt;br /&gt;
&lt;br /&gt;
==Funding==&lt;br /&gt;
*Australian College of Ambulance Professionals (ACAP)&lt;br /&gt;
*FlaemNuova (equipment)&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category:EBQ]]&lt;/div&gt;</summary>
		<author><name>EdMason</name></author>
	</entry>
</feed>